Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHAYLA M BERGMANN

Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology

NPI
1730143645
CMS profile
214770
Location
BEAUFORT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$33,400.59

36 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $19,559.24 24
Shire North American Group Inc $5,277.08 3
Novo Nordisk Inc $4,318.00 1
Genentech USA, Inc. $4,246.27 8

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHAYLA M BERGMANN

NPI 1730143645 · CMS profile ID 214770

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology

BEAUFORT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730143645?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730143645?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730143645?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1730143645?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

36 matching records · $33,400.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 36 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–36 of 36.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $4,318.0011/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750696189 CMS
Novartis Pharmaceuticals Corporation $147.0611/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156539 CMS
Novartis Pharmaceuticals Corporation $262.1911/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156543 CMS
Novartis Pharmaceuticals Corporation $1,750.0011/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156550 CMS
Novartis Pharmaceuticals Corporation $23.8111/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156557 CMS
Novartis Pharmaceuticals Corporation $125.6311/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156563 CMS
Novartis Pharmaceuticals Corporation $15.0011/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156567 CMS
Novartis Pharmaceuticals Corporation $454.0011/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156495 CMS
Novartis Pharmaceuticals Corporation $120.1011/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156533 CMS
Novartis Pharmaceuticals Corporation $238.5611/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156501 CMS
Novartis Pharmaceuticals Corporation $391.5111/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156505 CMS
Novartis Pharmaceuticals Corporation $4,880.0011/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156511 CMS
Novartis Pharmaceuticals Corporation $120.2611/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156517 CMS
Novartis Pharmaceuticals Corporation $21.7111/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156522 CMS
Novartis Pharmaceuticals Corporation $572.0011/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156527 CMS
Novartis Pharmaceuticals Corporation $267.0007/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658814037 CMS
Novartis Pharmaceuticals Corporation $280.0007/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658814043 CMS
Novartis Pharmaceuticals Corporation $303.2007/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156451 CMS
Novartis Pharmaceuticals Corporation $1,438.2007/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156457 CMS
Novartis Pharmaceuticals Corporation $3,660.0007/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156461 CMS
Novartis Pharmaceuticals Corporation $17.3107/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156467 CMS
Novartis Pharmaceuticals Corporation $627.5007/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156473 CMS
Novartis Pharmaceuticals Corporation $3,660.0007/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156479 CMS
Novartis Pharmaceuticals Corporation $121.8407/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156483 CMS
Novartis Pharmaceuticals Corporation $62.3607/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156489 CMS
Genentech USA, Inc. $48.0505/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681295443 CMS
Genentech USA, Inc. $172.8002/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681199071 CMS
Genentech USA, Inc. $3,100.0002/21/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681174603 CMS
Genentech USA, Inc. $21.4102/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681174651 CMS
Genentech USA, Inc. $83.5202/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681195977 CMS
Genentech USA, Inc. $452.6202/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681267795 CMS
Genentech USA, Inc. $337.8702/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681289719 CMS
Genentech USA, Inc. $30.0002/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681303669 CMS
Shire North American Group Inc $84.5801/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637788741 CMS
Shire North American Group Inc $30.0001/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637788743 CMS
Shire North American Group Inc $5,162.5001/03/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637788739 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $33,400.59 36
PY2020 $17,392.19 22
PY2021 $28,307.86 31
PY2022 $56,578.29 50
PY2023 $25,272.75 24
PY2024 $93,551.59 58
PY2025 $32,786.96 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $182,096.67 57
PY2024 Recipient $330.00 1
PY2024 Principal investigator $123,216.25 29
PY2023 Recipient $7,690.97 4
PY2023 Principal investigator $204,898.80 60
PY2022 Recipient $2,500.00 1
PY2022 Principal investigator $196,214.82 57
PY2021 Principal investigator $297,011.90 78
PY2020 Principal investigator $507,163.73 79
PY2019 Recipient $14,782.04 33
PY2019 Principal investigator $370,237.09 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

78 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,135.00 12/27/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 816790161
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,080.00 12/27/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 816790503
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $757.00 12/27/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 816790513
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 12/27/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 816790523
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 12/27/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 816790533
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,000.00 12/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A GLOBAL, OPEN-LABEL, MULTICENTER, PHASE 1/2 STUDY OF THE SAFETY AND DOSE ESCALATION OF BAX 888, AN ADENO-ASSOCIATED VIRUS SEROTYPE 8 (AAV8) VECTOR EXPRESSING B-DOMAIN DELETED FACTOR VIII (BDD-FVIII) IN SEVERE HEMOPHILIA A SUBJECTS ADMINISTERED A SINGLE INTRAVENOUS INFUSION No dispute reported 06/30/2026 816789429
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,250.00 12/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A GLOBAL, OPEN-LABEL, MULTICENTER, PHASE 1/2 STUDY OF THE SAFETY AND DOSE ESCALATION OF BAX 888, AN ADENO-ASSOCIATED VIRUS SEROTYPE 8 (AAV8) VECTOR EXPRESSING B-DOMAIN DELETED FACTOR VIII (BDD-FVIII) IN SEVERE HEMOPHILIA A SUBJECTS ADMINISTERED A SINGLE INTRAVENOUS INFUSION No dispute reported 06/30/2026 816789437
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 12/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A GLOBAL, OPEN-LABEL, MULTICENTER, PHASE 1/2 STUDY OF THE SAFETY AND DOSE ESCALATION OF BAX 888, AN ADENO-ASSOCIATED VIRUS SEROTYPE 8 (AAV8) VECTOR EXPRESSING B-DOMAIN DELETED FACTOR VIII (BDD-FVIII) IN SEVERE HEMOPHILIA A SUBJECTS ADMINISTERED A SINGLE INTRAVENOUS INFUSION No dispute reported 06/30/2026 816789447
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,100.00 12/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A GLOBAL, OPEN-LABEL, MULTICENTER, PHASE 1/2 STUDY OF THE SAFETY AND DOSE ESCALATION OF BAX 888, AN ADENO-ASSOCIATED VIRUS SEROTYPE 8 (AAV8) VECTOR EXPRESSING B-DOMAIN DELETED FACTOR VIII (BDD-FVIII) IN SEVERE HEMOPHILIA A SUBJECTS ADMINISTERED A SINGLE INTRAVENOUS INFUSION No dispute reported 06/30/2026 816789457
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 12/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A GLOBAL, OPEN-LABEL, MULTICENTER, PHASE 1/2 STUDY OF THE SAFETY AND DOSE ESCALATION OF BAX 888, AN ADENO-ASSOCIATED VIRUS SEROTYPE 8 (AAV8) VECTOR EXPRESSING B-DOMAIN DELETED FACTOR VIII (BDD-FVIII) IN SEVERE HEMOPHILIA A SUBJECTS ADMINISTERED A SINGLE INTRAVENOUS INFUSION No dispute reported 06/30/2026 816789467
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 12/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A GLOBAL, OPEN-LABEL, MULTICENTER, PHASE 1/2 STUDY OF THE SAFETY AND DOSE ESCALATION OF BAX 888, AN ADENO-ASSOCIATED VIRUS SEROTYPE 8 (AAV8) VECTOR EXPRESSING B-DOMAIN DELETED FACTOR VIII (BDD-FVIII) IN SEVERE HEMOPHILIA A SUBJECTS ADMINISTERED A SINGLE INTRAVENOUS INFUSION No dispute reported 06/30/2026 816789477
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 12/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A GLOBAL, OPEN-LABEL, MULTICENTER, PHASE 1/2 STUDY OF THE SAFETY AND DOSE ESCALATION OF BAX 888, AN ADENO-ASSOCIATED VIRUS SEROTYPE 8 (AAV8) VECTOR EXPRESSING B-DOMAIN DELETED FACTOR VIII (BDD-FVIII) IN SEVERE HEMOPHILIA A SUBJECTS ADMINISTERED A SINGLE INTRAVENOUS INFUSION No dispute reported 06/30/2026 816789487
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 12/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A GLOBAL, OPEN-LABEL, MULTICENTER, PHASE 1/2 STUDY OF THE SAFETY AND DOSE ESCALATION OF BAX 888, AN ADENO-ASSOCIATED VIRUS SEROTYPE 8 (AAV8) VECTOR EXPRESSING B-DOMAIN DELETED FACTOR VIII (BDD-FVIII) IN SEVERE HEMOPHILIA A SUBJECTS ADMINISTERED A SINGLE INTRAVENOUS INFUSION No dispute reported 06/30/2026 816789499
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,100.00 12/21/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GLOBAL EPIDEMIOLOGIC STUDY OF PREEXISTING IMMUNITY TO AAV IN ADULTS WITH SEVERE HEMOPHILIA No dispute reported 06/30/2026 816788863
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,207.00 12/08/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 816783334
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 12/08/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 816783345
Principal investigator 1 Global Blood Therapeutics, Inc. $4,315.00 11/19/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GBT_440-041_3939_01 No dispute reported 06/30/2026 849775323
Principal investigator 1 Global Blood Therapeutics, Inc. $1,715.00 11/19/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GLOBA002_GBT440-032_80036131 No dispute reported 06/30/2026 849775347
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,817.00 11/10/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 816774997
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $236.80 11/10/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 816775007
Principal investigator 1 CSL Behring $22.14 10/27/2021 Non-covered Recipient Entity
Medical Univ Of South Carolina - Comprehensive Sickle Cell Clinic
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 819675895
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,080.00 09/15/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 816759613
Principal investigator 1 CSL Behring $2,666.18 09/08/2021 Non-covered Recipient Entity
Medical Univ Of South Carolina - Comprehensive Sickle Cell Clinic
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 819675889
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 09/06/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 816757449
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $715.00 09/06/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 816757459
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,772.00 09/01/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 816756421
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,582.00 09/01/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 816756429
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,184.00 09/01/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 816756439
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $123.10 09/01/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 816756449
Principal investigator 1 Novo Nordisk AS $3,170.18 07/26/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 811327625
Principal investigator 1 Novo Nordisk AS $2,000.00 07/26/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 811330283
Principal investigator 1 Novo Nordisk AS $1,000.00 07/26/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 811635459
Principal investigator 1 Novo Nordisk AS $750.00 07/26/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 811866503
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,796.40 07/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 816744981
Principal investigator 1 Global Blood Therapeutics, Inc. $17,402.00 07/20/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GBT_440-041_3939_01 No dispute reported 06/30/2026 849774695
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,207.00 07/01/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 816736483
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,514.00 07/01/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 816736493
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 07/01/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 816736503
Principal investigator 1 Novo Nordisk AS $670.00 06/30/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 811635463
Principal investigator 1 Novo Nordisk AS $1,200.00 06/30/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 811866501
Principal investigator 1 Novo Nordisk AS $1,000.00 06/30/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 811866505
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,207.00 06/03/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 816729815
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,434.00 06/03/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 816729823
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,514.00 06/03/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 816729833
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 06/03/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 816729843
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,050.00 06/02/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 816729435
Principal investigator 1 Global Blood Therapeutics, Inc. $5,716.00 05/20/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VOXELOTOR (GBT440) IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 849774529
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,290.60 05/20/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 816725971
Principal investigator 1 Global Blood Therapeutics, Inc. $7,207.00 05/12/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VOXELOTOR (GBT440) IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 849774439
Principal investigator 1 Global Blood Therapeutics, Inc. $2,271.00 05/12/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VOXELOTOR (GBT440) IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 849774445
Principal investigator 1 Global Blood Therapeutics, Inc. $1,268.00 05/12/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VOXELOTOR (GBT440) IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 849774453
Principal investigator 1 Global Blood Therapeutics, Inc. $1,235.00 05/12/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VOXELOTOR (GBT440) IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 849774457
Principal investigator 1 Global Blood Therapeutics, Inc. $1,000.00 05/12/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VOXELOTOR (GBT440) IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 849774463
Principal investigator 1 Global Blood Therapeutics, Inc. $750.00 05/12/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VOXELOTOR (GBT440) IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 849774469
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,594.80 05/11/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 816721037
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,000.00 05/05/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GLOBAL EPIDEMIOLOGIC STUDY OF PREEXISTING IMMUNITY TO AAV IN ADULTS WITH SEVERE HEMOPHILIA No dispute reported 06/30/2026 816719667
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,950.00 05/05/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GLOBAL EPIDEMIOLOGIC STUDY OF PREEXISTING IMMUNITY TO AAV IN ADULTS WITH SEVERE HEMOPHILIA No dispute reported 06/30/2026 816719677
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 05/05/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GLOBAL EPIDEMIOLOGIC STUDY OF PREEXISTING IMMUNITY TO AAV IN ADULTS WITH SEVERE HEMOPHILIA No dispute reported 06/30/2026 816719689
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,062.00 05/05/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GLOBAL EPIDEMIOLOGIC STUDY OF PREEXISTING IMMUNITY TO AAV IN ADULTS WITH SEVERE HEMOPHILIA No dispute reported 06/30/2026 816719699
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,354.50 03/03/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 816695063
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $472.00 03/01/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 816693105
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,875.00 02/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 816691503
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,757.00 02/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 816691513
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,250.00 02/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 816691523
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 02/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 816691533
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,482.00 02/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 816691543
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $845.00 02/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 816691549
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $455.00 02/22/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 816691559
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,600.00 02/12/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A GLOBAL, OPEN-LABEL, MULTICENTER, PHASE 1/2 STUDY OF THE SAFETY AND DOSE ESCALATION OF BAX 888, AN ADENO-ASSOCIATED VIRUS SEROTYPE 8 (AAV8) VECTOR EXPRESSING B-DOMAIN DELETED FACTOR VIII (BDD-FVIII) IN SEVERE HEMOPHILIA A SUBJECTS ADMINISTERED A SINGLE INTRAVENOUS INFUSION No dispute reported 06/30/2026 816688775
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,217.70 02/10/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 816688282
Principal investigator 1 Novartis Pharmaceuticals Corporation $56,571.36 01/27/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PROSPECTIVE PHASE II, OPEN-LABEL, SINGLE-ARM, MULTICENTER, STUDY TO ASSESS EFFICACY AND SAFETY OF SEG101 (CRIZANLIZUMAB), IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM No dispute reported 06/30/2026 800633979
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 01/25/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 816683837
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 01/25/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 816683845
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 01/25/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 816683855
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,050.00 01/25/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 816683865
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $650.00 01/25/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 816683875
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,200.00 01/20/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 816682263
Principal investigator 1 Novartis Pharmaceuticals Corporation $66,366.14 01/14/2021 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITHOUT HYDROXYUREA HYDROXYCARBAMIDE IN SEQUENTIAL DESCENDING AGE GROUPS OF PEDIATRIC SICKLE CELL DISEASE PATIENTS WITH VASO OCCLUSIVE CRISIS No dispute reported 06/30/2026 800633765